Abbott Laboratories (ABT)

[DewDiligence]

ABT 1Q22 Results by Business Segment

  
                  %Corp      YoY Growth     
 Segment          Sales   (const currency)    
 Medical devices*  30%       +12% 
 Diagnostics       44%       +35% 
 Nutrition         16%        -4% 
 Drugs†            10%       +13%

1Q22 COVID-diagnostics sales were $3.3B (vs $2.3B in 4Q21), 62% of total 1Q22 diagnostics sales and 28% of total 1Q22 corporate sales.

Nutrition sales in the US were hampered by the infant-formula recall in Feb 2022 (#msg-168576155, #msg-167958896).

58% of overall corporate sales were ex-US.

*Includes diabetes care.
†Branded generics in emerging markets.